| Abstract | In a double-blind crossover study of the effects of the antigonadotropin danazol on pain and nodularity in 28 women with cyclical mastalgia danazol was given at doses of 200 mg/day and 400 mg/day, and the responses were assessed both subjectively and objectively. Danazol caused a significant and progressive decrease in breast pain and nodularity when compared with placebo. Symptoms responded more quickly with the 400 mg/day dose of danazol than with the 200 mg dose, but the larger dose also caused greater side-effects. Danazol is a useful addition to the range of antihormones that can be used to suppress the symptoms of severe hormone-related benign breast disease. |
| Authors | R E Mansel, J R Wisbey, L E Hughes |
| Journal | Lancet
(Lancet)
Vol. 1
Issue 8278
Pg. 928-30
(Apr 24 1982)
ISSN: 0140-6736 ENGLAND |
| PMID | 6122770
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
| Chemical References |
- Gonadotropins
- Pregnadienes
- Danazol
|
| Topics |
- Adult
- Breast Diseases
(drug therapy)
- Clinical Trials as Topic
- Danazol
(adverse effects, pharmacology, therapeutic use)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Gonadotropins
(antagonists & inhibitors)
- Humans
- Pain
(drug therapy)
- Pregnadienes
(therapeutic use)
- Random Allocation
|
